Cidara Therapeutics, Inc.
CDTX
Clasificación en acciones
#3191
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Precio por acción
$221.38
Última sincronización: 2026-01-08
Capitalización bursátil
$5.61B
Cambio (1 día)
0.00%
Cambio (1 año)
120.15%
País
US
Comercio Cidara Therapeutics, Inc. (CDTX)
Categoría
Healthcare
Ingresos de Cidara Therapeutics, Inc. (CDTX)
Ingresos en Sep 2025 TTM: 0.00
Según los últimos informes financieros de Cidara Therapeutics, Inc., los ingresos actuales de la empresa (TTM) son 0.00. En 2023, la empresa obtuvo unos ingresos de $23.28M una disminución en comparación con los ingresos del año 2022, que fueron de $64.45M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Cidara Therapeutics, Inc. desde 2012 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | $1.28M | -94.52% |
| 2023 | $23.28M | -63.87% |
| 2022 | $64.45M | 30.01% |
| 2021 | $49.57M | 310.81% |
| 2020 | $12.07M | -42.30% |
| 2019 | $20.92M | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| - | - |
CH
|
|
| $6.02B | - |
NL
|
